Recent Transactions

Advised Hero Brands on the strategic investment in GDK by True. GDK is a leading Middle Eastern quick-service restaurant brand, with over 145 franchised locations in the UK and 170 globally, including the US, Canada, Sweden and the Middle East

Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)

Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of  pharmaceutical solutions and diagnostic tests for rare diseases

Advised Danone on its acquisition of Functional Formularies, a leading whole foods tube feeding business in the US, from Swander Pace Capital

Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH

Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

Advising Pet Circle, Australia’s leading online specialty pet company, on its unicorn Series C funding round, which included a A$125m primary capital raise

Advised Lion, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings, on the acquisition of Bell’s Brewery, a leading US independent craft brewery

Advised Youfoodz Holdings Limited, a leading provider of fresh, ready-made meals and other convenience food products, on its cash sale to HelloFresh SE via scheme of arrangement

Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia

Advised Henkel on its brand divestment program (including the sale of the General, Right Guard and Dry Idea brands)

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

Advised Micreos, a fast-growing biotechnology company, on a long-term license agreement with L’Oréal for one of Micreos’ phage-based active ingredients, SA.100

Advised the Ad-Hoc Group of First Lien and Second Lien Lenders on consensual out-of-court amend & extend

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma

Advised Viscofan (BME:VIS), the #1 producer of artificial casings for the meat industry worldwide (>30% market share), on the acquisition of Nitta Casings and Nitta Casings Canada (“NCI” and “NCCI”) one of the leading brands in the production of collagen casings in North America, from Nitta Gelatin (TSE:4977)  

Advised Apax Partners, a global investment firm, on the sale of Grupo Electro Stocks, a leading Spanish distributor of electrical materials, to the Electrical Wholesale business unit within the Würth Group, a global leader in the distribution of assembling and fastening materials

Advised Lion, an Australian subsidiary of Kirin, on its acquisition of a strategic stake in Four Pillars Gin, Australia’s leading craft gin distillery

Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company

Advised Finaccess Capital, an investment company with a strong presence in the casual dining and quick service restaurant sector, on its 75% partial takeover of Restaurant Brands New Zealand, a corporate franchisee specialising in managing multi-site branded food retail chains (with brands consisting of KFC, Pizza Hut, Taco Bell and Carl’s Jr.)

Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

Advised Lion, an Australian subsidiary of Kirin, on its acquisition of a strategic stake in Remedy Kombucha, Australia’s leading producer and distributer of kombucha beverages

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Australian wine business Fine Wine Partners to Accolade Wines, a portfolio company of CHAMP Private Equity

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

Advised Patties Foods Ltd (ASX:PFL), the leading Australian branded frozen food Company, with market leadership in the frozen savoury and frozen dessert segments, on its proposed sale to Pacific Equity Partners via Scheme of Arrangement

Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV

Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities

Advised Kerry Group plc, a global leader in food ingredients and flavor technologies, on the sale of its Australian subsidiary Kerry Pinnacle, an integrated manufacturer and distributor of bakery ingredients and prepared bakery products, to Pacific Equity Partners

Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Everyday Cheese business to Warrnambool Cheese & Butter, a listed Australian dairy company controlled by the Canadian dairy player Saputo

Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.

Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc

Advised Inchcape plc, the leading independent international automotive distributor and retailer, on the acquisition of Trivett Automotive Group, the leading luxury and premium automotive group in Australia

Advised Woolworths Limited, Australia’s largest supermarket operator, on the sale of its Consumer Electronics retail chain, Dick Smith Electronics, to Anchorage Capital Partners

Provided fairness opinion to the Executive Management Board of WMF in connection with the voluntary public takeover offer by Finedining Capital GmbH, a holding company in the possession of funds managed by Kohlberg Kravis Roberts & Co. L.P.

Advised Robert Wiseman Dairies PLC, the UK’s largest processor of fresh milk, on a recommended offer from Unternehmensgruppe Theo Müller S.e.c.s.

Advised Super Retail Group on the acquisition of Rebel Group Limited, Australia’s largest retailer of sporting goods, for A$610 million and the associated A$334 million capital raising used to fund the acquisition

Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics

Advised Pacific Equity Partners and ANZ, the shareholders of Tegel Foods (Tegel), on the sale of Tegel, New Zealand’s preeminent producer of poultry products, to Affinity Equity Partners

Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK

Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment

Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany

Advised Nestlé on the agreed cash offer for the US pet-food company Ralston Purina